# Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

> **NCT00358657** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Immunodeficiency Syndrome
- Severe Aplastic Anemia
- Genetic Disorder

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **RADIATION:** Total-Body Irradiation

## Key facts

- **NCT ID:** NCT00358657
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05-24
- **Primary completion:** 2018-08-17
- **Final completion:** 2019-05-25
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2021-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358657, "Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT00358657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*